Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by kmuchaon Aug 31, 2018 12:55pm
138 Views
Post# 28549449

RE:RE:RE:RE:RE:Screw the long term investor= consolidation=reverse split

RE:RE:RE:RE:RE:Screw the long term investor= consolidation=reverse splitI hear ya...too many people take these posts personally and get all fired up lol.


"I would still rather have the original 100,000 shares rise to $10/sh= $1,000,000
then a post consolidation of 10,000 shares rise to $50, $60 , $70. $80. $90 = $500,000 etc etc.
 
Bottom line the 10,000 shares would have to hit $100/sh to equal pre RS profit"

$10/share and $100/share is the same thing if it splits 10:1 just like the example I used of $0.30 and $3.00.

So if PMN splits 10:1 the shares will go up 10x automatically from the split and then trade up or down from there (because it's based on what it's worth...all of a sudden a RS doesn't make the company worth way less or more....pre split market cap is 75 mil, when it splits it will be right around there....it won't drop the market cap to 35 mil).

If PMN goes from $0.30 to $10 share with no split, in theory if it splits it still will go from $3.00 to $100....it's the same magnitude of rise. 

I feel like I'm not explaining it well and it's tough to wrap your head around.

As for exposure and what not. I think, but could be wrong, USA institutions can't even buy PMN if it's not on a legit exchange like Nasdaq/NYSE (as opposed to OTC).....so all of a sudden if big time investors/groups can purchase PMN on those exchanges and they have to disclose their holdings...well it shows you where the big money is going. Some of these big companies can't even buy shares under $5 as well (internal company rules), so we're limited to who invetors can even be!


Either way I'm fine with what happens. I hope we can get a large milestone payment from another pipeline stream that can help us fund PMN310 and then maybe a split isn't even needed....time will tell I guess,
Bullboard Posts